Published: August 23, 2016

Introduction {#sec1}
============

Interleukin-2 (IL-2) directs the clonal expansion and differentiation of CD4^+^ and CD8^+^ regulatory, effector, and memory T cell populations. The IL-2 receptor (IL-2R) comprises IL-2Rβ:IL-2Rγ heterodimers and CD25, the α chain, which confers high-affinity binding of IL-2 to the receptor ([@bib27], [@bib41]). By coupling to the Janus family kinases JAK1 and JAK3, the IL-2R controls the Tyr phosphorylation and activation of Signal Transducer and Activator of Transcription 5 (STAT5) transcription factors ([@bib27], [@bib41]). The biological importance of IL-2 has prompted interest in therapeutic manipulation of IL-2 signaling. Drugs to block IL-2-JAK signaling are one approach to modulate adaptive immune responses ([@bib41], [@bib50]), but there is increasing interest in using engineered cytokines or cytokine antibodies to selectively modulate, rather than ablate, IL-2 signaling ([@bib2], [@bib35], [@bib51]).

Rational manipulation of IL-2 signaling is limited by the lack of information about its full complexity. In particular, there is growing recognition that IL-2 signaling extends beyond STATs and includes signaling networks controlled by guanosine-5′-triphosphate hydrolases (GTPases) and lipid and serine/threonine (Ser/Thr) kinases. IL-2-induced metabolic and transcriptional programs are regulated by the Ser/Thr kinase, mammalian target of rapamycin complex 1 (mTORC1) ([@bib17], [@bib48]). IL-2 also drives the accumulation of active, guanosine-5′-triphosphate (GTP)-bound Ras GTPases and activation of the Raf-MAPK-ERK MAP kinase cascade ([@bib27]). Moreover, IL-2-maintained T cells accumulate phosphatidylinositol (3,4,5)-trisphosphate (PIP~3~) ([@bib11]), the product of phosphatidylinositol 3-kinases (PI3K). This lipid binds to the pleckstrin homology (PH) domain of the Ser/Thr kinase AKT and coordinates its activation by phosphoinositide-dependent protein kinase-1 (PDK1) ([@bib37]). The strength and duration of AKT activity then direct T cell transcriptional programs that determine T cell fate ([@bib32]).

In terms of the potential complexity of IL-2 signaling, IL-2-maintained cytotoxic T cells (CTLs) express ∼250 protein kinases and 120 protein phosphatases ([@bib22]). However, the details of how IL-2R occupancy impacts protein phosphorylation networks in CTLs are not mapped. Moreover, while JAK1 and JAK3 are critical for IL-2 signal transduction, it is not known if the IL-2R couples to Ser/Thr kinases solely by JAK activation. Thus, IL-2 signaling has been reported to involve SRC family kinases such as lymphocyte-specific protein tyrosine kinase (LCK) ([@bib19], [@bib21], [@bib25]) and FYN ([@bib25]). The importance of intrinsic SRC family kinase activity for antigen receptor signaling in T cells is well documented ([@bib8], [@bib40]). In contrast, the role of SRC kinases in cytokine signaling processes is not understood.

Accordingly, we used mass-spectrometry-based quantitative phosphoproteomics to explore IL-2-controlled protein phosphorylation pathways in primary CD8^+^ effector cytotoxic T cells where IL-2 directs the transcriptional programs that control proliferation and effector functions. Our data mapped many previously unrecognized IL-2-controlled phosphorylations and uncovered the diversity and intricacy of signaling pathways influenced by IL-2. We also detected a network of IL-2-independent phosphorylations mediated by SRC family kinases in CTLs. This JAK-independent signaling controlled PIP~3~ levels and AKT activity in CTLs. Our data provide a valuable resource of IL-2-mediated phosphorylations and force a revision of the models of IL-2 as a signaling switch for PIP~3~-AKT signaling. Additionally, the data give new ideas for therapeutic modulation of key pathways that control CTL fate.

Results {#sec2}
=======

The IL-2-Regulated Phosphoproteome {#sec2.1}
----------------------------------

To produce effector CTLs, antigen-primed P14 TCR transgenic CD8^+^ T cells were clonally expanded in IL-2. For phosphoproteomic work, we used SILAC and quantitative high-resolution mass spectrometry following a protocol where CTLs were lysed and digested with trypsin and phosphopeptides enriched by HILIC fractionation followed by TiO~2~ affinity chromatography and analysis on an LTQ-Orbitrap Velos ([Figure 1](#fig1){ref-type="fig"}A). To examine IL-2-regulated phosphorylations, CTLs were quiesced by 24 hr of IL-2 deprivation and then rechallenged with IL-2 for 15 min. One complication of IL-2 deprivation experiments in primary non-transformed T cells is that IL-2 is required for CTL survival and for the expression of the high-affinity IL-2R complex. Accordingly, we cultured IL-2-deprived CTLs in IL-12, which maintains cell viability and supports expression of IL-2Rs and IL-2 responsiveness. The collective analysis of data from three biological replicates of IL-2-deprived versus IL-2-stimulated CTLs identified 6,458 phosphorylations on 2,248 proteins ([Figure 1](#fig1){ref-type="fig"}B and [Table S1](#mmc2){ref-type="supplementary-material"}). The total number of phosphosites identified in the individual biological replicates was similar ([Figure 1](#fig1){ref-type="fig"}C). In each replicate, IL-2 increased phosphorylation on ∼10% of the identified phosphorylation sites and decreased ∼4% of the quantified phosphorylations ([Figure 1](#fig1){ref-type="fig"}D). Activation of IL-2 signaling was verified in all three replicates by the reproducible detection of a robust increase in phosphorylation of STAT5A pY694 and STAT5B pY699. Western blot analysis also confirmed the IL-2 responsiveness of IL-2-deprived and IL-12-maintained CTLs, showing strong induction of STAT5A pY694, STAT5B pY699, and ERK1 and/or ERK2, pT202, and pY204 phosphorylations ([Figure 1](#fig1){ref-type="fig"}E). Collectively, these experiments identified ∼700 phosphosites that were increased and ∼220 phosphosites that were decreased in response to IL-2 stimulation of CTLs ([Figure 1](#fig1){ref-type="fig"}B). Thus, IL-2 both positively and negatively regulated protein phosphorylations in CTL.

This phosphoproteome analysis revealed that evaluating STAT5A pY694 and STAT5B pY699 phosphorylation gives a limited perspective of IL-2 signaling. For example, IL-2 induced a strong Tyr phosphorylation of three adaptor proteins: GRAP2/GADS (pY45), GAB3 (pY569), and SHC1 (pY313) ([Figure 1](#fig1){ref-type="fig"}F). However, our dataset provided an extensive mapping of the impact of IL-2 on the Ser/Thr phosphoproteome. For example, phosphorylation of Ser/Thr kinases, STK17B (DRAK2) and CAMKIV, was reproducibly increased by IL-2. The Ser phosphorylation of Stathmin, a protein that controls microtubule assembly, and the actin regulator, L-plastin (LCP1), was increased with a similar magnitude to STAT5 Tyr phosphorylation ([Figure 1](#fig1){ref-type="fig"}B and [Table S2](#mmc3){ref-type="supplementary-material"}). The functional diversity of IL-2-regulated phosphoproteins was striking; IL-2 equally targeted proteins linked to gene transcription and regulators of GTPases and RNA ([Figure 1](#fig1){ref-type="fig"}G and [Table S3](#mmc4){ref-type="supplementary-material"}). Notably, the regulation of GTPase-activating proteins (GAPs) and guanine nucleotide exchange factors (GEFs) for Rac, CDC42, and RHO, as well as Cofilin1 and 2, and actin ([Figure 1](#fig1){ref-type="fig"}H and [Table S3](#mmc4){ref-type="supplementary-material"}) revealed that IL-2 signaled to the actin cytoskeleton. IL-2-controlled phosphorylation of regulators of ADP ribosylation factors (ARFs) and Ras-like proteins in brain (RABs), in addition to VAMP3, DENND4C, and EXOC7 indicated that IL-2 signaled to molecules that control intracellular vesicle transport and exocytosis ([Figure 1](#fig1){ref-type="fig"}H).

IL-2 Regulation of the Nuclear Environment and mRNA Translational Machinery {#sec2.2}
---------------------------------------------------------------------------

IL-2 controls transcriptional programs to promote CTL terminal differentiation ([@bib32], [@bib45]). In addition to the Tyr phosphorylations that promote STAT5 DNA binding, the present data showed that IL-2 controlled STAT5A S127 and S128 phosphorylation ([Figure 2](#fig2){ref-type="fig"}A). IL-2-induced Ser phosphorylation of STAT5 has been proposed to regulate STAT5 transcriptional function ([@bib4], [@bib10]). IL-2-regulated phosphoproteins included other transcription factors such as MYC and NFIL3A; proteins that modify histones and chromatin; DNA helicases; and constituents of the RNA polymerase II machinery such as TAF3---a TFIID subunit---and the RNA polymerase II subunit A C-terminal domain phosphatase, CTDP1 ([Figure 2](#fig2){ref-type="fig"}A and [Table S2](#mmc3){ref-type="supplementary-material"}). IL-2 reproducibly increased TRIM28 S473 phosphorylation ([Figure 2](#fig2){ref-type="fig"}A). TRIM28 is a co-repressor that mediates transcriptional silencing and is important for T cell development and peripheral T cell homeostasis ([@bib9]). TRIM28 complexes with heterochromatin protein 1 (HP1) family proteins to control chromatin remodeling; the phosphorylation of S473 in TRIM28 inhibits HP1 binding and co-repressor function ([@bib7]). Together, these data expose the extensive influence IL-2 may have on transcription.

Implementation of gene expression relies on mRNA transcript processing and translation. Interestingly, IL-2 stimulated the phosphorylation of nuclear pore proteins, including Nup98 and Nup214, that are required for mRNA export into the cytoplasm ([Figure 2](#fig2){ref-type="fig"}A). IL-2 also controlled phosphorylations on proteins that direct RNA stability ([Figure 2](#fig2){ref-type="fig"}A). IL-2 stimulated phosphorylation of S100 in YBX1, a component of messenger ribonucleoprotein particles (mRNPs). This phosphorylation was validated using phospho-specific antibodies ([Figure 2](#fig2){ref-type="fig"}B). YBX1 binds to mRNAs to prevent their association with the translation initiation complex: phosphorylation of YBX1 on S100 blocks mRNA binding, thereby permitting translation of YBX1 binding mRNAs ([@bib16]).

Thus, the current data argue that IL-2 has the potential to coordinate the composition of the nuclear proteome, the function of the nuclear pore, and the RNA binding capability of mRNPs to orchestrate which gene transcripts are processed into protein in CTLs. Additionally, we noted that IL-2 regulated the phosphorylation of key components of the translational machinery, e.g., EIF5B ([Figure 2](#fig2){ref-type="fig"}C), which is critical for translation initiation, including stabilizing the association of the initiation methionine-tRNA with the ribosome and regulating ribosome assembly ([@bib26]). The phosphoproteomic dataset also confirmed previous observations that IL-2 regulates the activity of mTORC1 ([Figure 2](#fig2){ref-type="fig"}C), a kinase that controls mRNA translation and protein degradation pathways and shapes the CTL proteome ([@bib22]).

JAK-Controlled Phosphorylation Pathways in CTLs {#sec2.3}
-----------------------------------------------

The Tyr kinases JAK1 and JAK3 are important for IL-2 signaling, but their role in regulating CTL phosphoproteomes has not been defined. Accordingly, we used SILAC-based mass spectrometry to compare the phosphoproteome of CTLs maintained in IL-2 alone both before and after a 30-min or 4-hr treatment with the JAK3 and JAK1 inhibitor, Tofacitinib. The ability of Tofacitinib to inhibit JAKs was verified by its ability to cause a rapid and sustained loss of STAT5 Tyr phosphorylation ([Figure 3](#fig3){ref-type="fig"}A). The collective analysis of three biological replicates for the 30-min Tofacitinib treatment identified 8,839 phosphosites on 3,086 proteins ([Figure 3](#fig3){ref-type="fig"}B and [Table S4](#mmc5){ref-type="supplementary-material"}). In each replicate, Tofacitinib decreased phosphorylation on ∼4% of the identified phosphorylation sites ([Figure S1](#mmc1){ref-type="supplementary-material"}A). It was also striking that Tofacitinib caused an increase in ∼4% of the detected phosphoproteome ([Figure 3](#fig3){ref-type="fig"}B). Collectively, these experiments identified 283 phosphosites that were decreased and 237 phosphosites that were increased in response to 30 min of Tofacitinib treatment of CTLs ([Figure 3](#fig3){ref-type="fig"}B). Following 4 hr of Tofacitinib treatment, we identified 11,822 phosphosites in CTLs from 3,499 proteins ([Figure 3](#fig3){ref-type="fig"}C and [Table S5](#mmc6){ref-type="supplementary-material"}). In total, we identified 450 downregulated and 185 upregulated phosphorylations in the 4-hr Tofacitinib-treated CTLs ([Figure 3](#fig3){ref-type="fig"}C).

Both datasets confirmed that Tofacitinib treatment caused a rapid and sustained loss of STAT5A and STAT5B Tyr phosphorylation but also revealed a decrease of the IL-2-regulated Tyr phosphorylations in SHC1 (pY313) and GAB3 (pY569) ([Figure 3](#fig3){ref-type="fig"}D). The rapidity in the loss of IL-2-regulated Tyr phosphorylations following JAK inhibition is consistent with high levels and/or activity of protein Tyr phosphatases in CTLs. Additionally, Tofacitinib treatment impacted the Ser/Thr phosphorylation network in CTLs; the ratio of pS:pT:pY in the Tofacitinib-regulated phosphosites was 35:6.5:1. Indeed, there were striking changes to a core set of pS and pT phosphorylations at both the 30-min and 4-hr time points ([Table S6](#mmc7){ref-type="supplementary-material"}). Moreover, there was clear reciprocal regulation of Ser/Thr phosphorylation sites modulated by IL-2 and Tofacitinib ([Figure 3](#fig3){ref-type="fig"}E), including those in L-plastin, Stathmin, DENND4C, and STAT5. These data indicate that an IL-2-JAK1/3 pathway controlled diverse Ser/Thr kinases in CTLs. In particular, the phosphoproteomics indicated that JAKs couple IL-2Rs to regulation of mRNA stability and translation and, hence, protein synthesis ([Figure 3](#fig3){ref-type="fig"}F), as there was reciprocal regulation of the phosphorylation of YBX1, LARP1, LARP4B, and EIF3A by IL-2 and Tofacitinib ([Figure 3](#fig3){ref-type="fig"}E). We tested this hypothesis using a sensitive single-cell assay that quantifies the catalytic incorporation of an analog of puromycin, an aminoacyl-tRNA mimetic, into elongating nascent protein chains in the ribosome. IL-2-stimulated CTLs have high protein synthesis and a high protein content compared to CTLs treated with Tofacitinib or CTLs cultured without cytokine ([Figures 3](#fig3){ref-type="fig"}G and 3H). The prediction from phosphoproteomics was thus correct: IL-2-JAK signaling pathways are essential for protein synthesis and maintenance of CTL mass.

Evidence for Tofacitinib Insensitive IL-2 Signaling in CTLs {#sec2.4}
-----------------------------------------------------------

Interestingly, we uncovered some discordance between the IL-2- and Tofacitinib-regulated phosphoproteomes. Notably, IL-2 stimulation triggered dephosphorylation of a number of proteins that did not show increased phosphorylation in response to Tofacitinib inhibition of JAK3 and/or JAK1 ([Figures 4](#fig4){ref-type="fig"}A--4C). For instance, Cofilin, an important regulator of actin filament dynamics, is inactivated by S3 phosphorylation and reactivated by S3 de-phosphorylation mediated by phosphatases such as slingshot 1 (SSH1) ([@bib36]). IL-2 stimulated dephosphorylation of Cofilin S3, yet phosphorylation on this site was not controlled by Tofacitinib ([Figure 4](#fig4){ref-type="fig"}C). Thus, IL-2 may orchestrate Tofacitinib-independent signaling pathways. It is also possible that there are different thresholds of JAK signaling needed for different responses. The Tofacitinib concentrations used herein totally blocked STAT5 phosphorylation, but it is impossible to exclude a small pool of JAK molecules that were inaccessible to the inhibitor. We also noted that some IL-2-regulated phosphorylations were only lost after sustained Tofacitinib treatment, e.g., STAT5A Y694 was dephosphorylated within 30 min of Tofacitinib treatment, whereas STAT5A S127 and S128 were only decreased in the 4-hr treatment. Protein dephosphorylation following kinase inhibition is determined by the activity of relevant phosphatases. The differential kinetics of STAT5 Tyr and Ser dephosphorylation informs about the relative abundance and/or activity of the STAT5 Tyr and Ser phosphatases. Hence, the finding that a significant subset of IL-2-stimulated phosphorylations was not decreased following 4 hr of Tofacitinib treatment ([Figures 4](#fig4){ref-type="fig"}A--4C) could reflect that these are very stable modifications due to low activity and/or accessibility of the relevant phosphatases.

IL-2- and JAK-Independent SRC Family Kinase Signaling Networks in CTLs {#sec2.5}
----------------------------------------------------------------------

The phosphoproteomic datasets identified 13,134 phosphosites on 3,706 proteins in CTLs that were not modulated by IL-2 or by Tofacitinib treatment ([Table S7](#mmc8){ref-type="supplementary-material"}). The majority of these were Ser/Thr phosphorylations but included a subset of 105 Tyr phosphorylations in 93 proteins comprising adaptor proteins and enzymes ([Figure 4](#fig4){ref-type="fig"}D). Among them were regulatory pY sites in the SRC kinases, LCK ([@bib12], [@bib34]) and FYN ([@bib33]); the Tec family Tyr kinases, TEC ([@bib54]) and TXK ([@bib6]); and the pseudokinase SGK223 ([@bib49]) ([Figure 4](#fig4){ref-type="fig"}E). Interestingly, the protein Tyr phosphatases, PTPN6/SHP-1 and PTPN11/SHP-2, were phosphorylated on key regulatory sites required for their optimal activity ([@bib14], [@bib29], [@bib56]) ([Figure 4](#fig4){ref-type="fig"}E). Notably, these Tyr phosphosites showed a strong representation of SRC family kinase consensus motifs and sites experimentally assigned as SRC family kinase substrates ([Table S8](#mmc9){ref-type="supplementary-material"}). These included the regulatory phosphorylation in the activating loop of TXK/RLK (pY420) and the corresponding phosphorylation in TEC (pY518) and pY170 in CD3 epsilon ([@bib15]). Moreover, we identified two well-characterized SRC substrates in non-lymphoid cells: pY118 in paxillin ([@bib55]) and pY44 in the metabolic enzyme, enolase ([@bib31], [@bib53]). CTLs co-express the SRC family kinases LCK and FYN, and the phosphoproteomic data revealed that these kinases were phosphorylated on sites associated with catalytic activation: pY394 in LCK and pY420 in FYN ([Figure 4](#fig4){ref-type="fig"}E). The SRC family kinase phosphorylation signature, particularly the activating phosphorylations of LCK and FYN, was not regulated by IL-2 or by Tofacitinib. The SRC kinase phosphorylation signature was identified in CTLs maintained in IL-2 alone and also in the quiescent CTLs maintained in IL-12. Moreover, phosphoproteomics analysis revealed that the SRC kinase signature was not increased by IL-12 treatment of IL-2-maintained CTLs ([Figure S2](#mmc1){ref-type="supplementary-material"}A). The data are consistent with previous reports that SRC family kinases are constitutively active in T cells ([@bib40]).

To explore LCK- and/or FYN-controlled phosphorylations in CTLs, we used the selective SRC family kinase inhibitor, PP2. This inhibitor did not prevent IL-2 activation of JAKs, as STAT5A Y694 and STAT5B Y699 phosphorylations were sustained in IL-2-maintained CTLs following exposure to PP2 ([Figure 5](#fig5){ref-type="fig"}A). Moreover, prolonged PP2 treatment did not cause loss of expression of CD25, a well-established JAK1/3-STAT5-regulated protein ([@bib23], [@bib24], [@bib28]) ([Figure 5](#fig5){ref-type="fig"}B), nor did PP2 mimic the impact of IL-2 withdrawal on CTL size ([Figure 5](#fig5){ref-type="fig"}C) or mass ([Figure 5](#fig5){ref-type="fig"}D). SILAC-based quantitative mass spectrometry analysis of IL-2-maintained CTLs, both before and after treatment with PP2, confirmed PP2 selectivity. Effective PP2 inhibition of LCK and/or FYN was emphasized by decreased phosphorylation of TXK/RLK pY420, Enolase pY44, paxillin pY118, SGK223 pY196, and PTPRα pY825 ([Figure 5](#fig5){ref-type="fig"}E), yet JAK1 and JAK3 signaling remained intact. PP2 treatment neither downregulated STAT5A pY694 and STAT5B pY699 phosphorylation ([Figure 5](#fig5){ref-type="fig"}E) nor modulated autophosphorylation sites of JAK1 (pY1033) or JAK3 (pY781). There was also little overlap in the Tyr phosphorylations downregulated by Tofacitinib versus PP2 ([Figure 5](#fig5){ref-type="fig"}E). For example, PP2 treatment also did not inhibit SHC1 pY313 Tyr phosphorylation ([Figure 5](#fig5){ref-type="fig"}E), a key step in the activation of the Ras-ERK1 and ERK2 pathway. Indeed, PP2 treatment did not inhibit ERK1 and ERK2 phosphorylation in IL-2-stimulated CTLs ([Figure 5](#fig5){ref-type="fig"}F).

Collectively, PP2 decreased 779 phosphorylations on 554 proteins and increased 469 phosphorylations on 349 proteins in CTLs ([Figures 5](#fig5){ref-type="fig"}G and [S2](#mmc1){ref-type="supplementary-material"}B and [Table S9](#mmc10){ref-type="supplementary-material"}). The limited overlap with the Tofacitinib-regulated phosphorylations ([Figure 5](#fig5){ref-type="fig"}H) consisted mainly of pS and pT sites. It was notable that phosphoproteins reproducibly regulated by PP2 were enriched in ATP-binding proteins, including diverse Ser/Thr kinases ([Figure 5](#fig5){ref-type="fig"}I and [Table S10](#mmc11){ref-type="supplementary-material"}). This impacted signaling by protein kinase C; protein kinase D2; the MAP kinase, ERK3; and the AMP family kinases SIK1, SIK2, and SIK3 ([Figure 5](#fig5){ref-type="fig"}J). The data also indicated that LCK- and/or FYN-mediated signaling restrains the activity of the MAP2K4-p38-MAPKAP2 Ser/Thr kinases ([Figure 5](#fig5){ref-type="fig"}J).

There were a small number of phosphorylations that were co-regulated by IL-2-JAK1/3 and SRC kinases ([Figure 6](#fig6){ref-type="fig"}A and [Table S11](#mmc12){ref-type="supplementary-material"}). These include mTORC1-controlled phosphorylations on ribosomal S6 proteins ([Figures 6](#fig6){ref-type="fig"}A and 6B). Flow cytometric quantification of S6 pS235 and/or pS236 phosphorylations using phospho-specific antibodies confirmed that IL-2-maintained CTLs have high levels of S6 phosphorylation that are downregulated in CTLs treated with either Tofacitinib, PP2, or the mTORC1 inhibitor rapamycin ([Figure 6](#fig6){ref-type="fig"}C). Moreover, western blot analysis of the phosphorylation of the mTORC1 substrate sequence on S6K1 (pT389) confirmed that activity of both JAKs and SRC kinases is required to sustain mTORC1 activity in CTLs ([Figure 6](#fig6){ref-type="fig"}D). Collectively, these data show that IL-2-JAK signaling coordinates with SRC-kinase-controlled phosphorylation pathways to control mTORC1 activity in CTLs.

SRC Family Kinase Regulation of PIP~3~-AKT Signaling Pathways in CTLs {#sec2.6}
---------------------------------------------------------------------

The Ser/Thr kinase AKT plays an important role in CTLs to regulate nuclear exclusion and function of the FOXO1 and FOXO3 transcription factors. These simultaneously induce and repress expression of genes encoding key effector and trafficking molecules to direct effector and/or memory CD8^+^ T cell differentiation ([@bib20]). It has been proposed that the PI3K-AKT-mTORC1 pathway is sensitive to JAK3 inhibition ([@bib50]). However, this conclusion is based on experiments with a new JAK3 inhibitor that monitored S6 phosphorylation as a surrogate for AKT activity ([@bib50]). The present data show that mTORC1-mediated phosphorylation of S6 in CTLs is also Tofacitinib sensitive ([Figures 6](#fig6){ref-type="fig"}C and 6D). However, a salient fact is that the activity of mTORC1 and the phosphorylation of S6 are independent of AKT or PI3K in CTLs ([@bib17], [@bib22]). Therefore, to assess the effect of JAK inhibitors on AKT activity, more direct assays and analyses are required.

The current mass spectrometry dataset had little coverage of AKT or AKT phosphosites reflecting biases against the detection of the R/K-X-R/K-X-X-pS/T-φ AKT substrate sequence when using trypsin for protein digestion ([@bib18]). We did detect one putative AKT substrate sequence, PRAS40/AKT1S1 T247 phosphorylation, which was increased following IL-2 stimulation but was neither modulated by Tofacitinib nor by PP2 treatment ([Figure 7](#fig7){ref-type="fig"}A).

To explore the role of IL-2 and JAKs in controlling AKT activity in more detail, we therefore adopted biochemical experiments. The activity of AKT is controlled by PDK1-mediated phosphorylation of T308 in the AKT catalytic domain. The association between AKT and PDK1 is facilitated both by PIP~3~ and the mTORC2-mediated phosphorylation of AKT on S473 ([@bib37]). Accordingly, we directly assessed the regulation of AKT phosphorylation by JAK and SRC kinase pathways. IL-2-cultured CTLs had high AKT T308 and S473 phosphorylation, which was lost if cells were treated with the PI3K-p110δ inhibitor, IC87114, or the allosteric inhibitor, AKTi, which prevents PIP~3~ binding to AKT ([Figure 7](#fig7){ref-type="fig"}B). These experiments showed that AKT activity in CTLs was dependent on sustained production of PIP~3~ and sustained interaction of PIP~3~ and AKT. CTLs treated with Tofacitinib lost STAT5 Tyr phosphorylation and decreased phosphorylation of AKT S473 ([Figure 7](#fig7){ref-type="fig"}B), but there was only a minimal effect of Tofacitinib on AKT T308 phosphorylation and no detectable effect of Tofacitinib on the phosphorylation of the FOXO1 pT24 and FOXO3 pT32 AKT substrate sequences ([Figure 7](#fig7){ref-type="fig"}B). However, PP2 blocked the phosphorylation of AKT T308 and FOXO1 pT24 and/or FOXO3 pT32 ([Figure 7](#fig7){ref-type="fig"}B). We also found that IL-2 deprivation for 60 min resulted in complete loss of STAT5, but not AKT phosphorylation ([Figure 7](#fig7){ref-type="fig"}C). Hence, SRC kinases pathways, rather than IL-2-JAK signaling, controlled AKT in CTLs. One role for AKT is to cause phosphorylation-mediated nuclear exclusion of FOXO1. We used two strategies to examine the impact of JAK and SRC kinases on the localization of FOXO1 in CTLs: microscopic analysis of intact cells and flow cytometry analysis of purified nuclei from CTLs expressing a FOXO1-GFP fusion protein. In IL-2-maintained CTLs, which have high AKT activity, FOXO1-GFP was predominantly localized to the cytoplasm ([Figures 7](#fig7){ref-type="fig"}D and 7E). When CTLs were treated with IC87114 ([Figure 7](#fig7){ref-type="fig"}F) or AKTi ([Figure 7](#fig7){ref-type="fig"}G), the FOXO1-GFP relocated to the nucleus. The majority of FOXO1-GFP also relocalized to the nucleus in PP2, but not Tofacitinib-treated, CTLs ([Figures 7](#fig7){ref-type="fig"}H--7J).

As PIP~3~ levels are rate limiting for AKT activation, the differential sensitivity of AKT phosphorylation and activity to PP2 and Tofacitinib raised the possibility that SRC kinases, rather than JAK signaling, controlled PIP~3~ levels in IL-2-maintained CTLs. Lipid measurements confirmed that PIP~3~ decreased in CTLs following PI3K-p110δ inhibition and PP2 treatment. However, there was no discernible effect of Tofacitinib on PIP~3~ levels in CTLs ([Figure 7](#fig7){ref-type="fig"}K). Importantly, cellular levels of phosphatidylinositol (4,5)-bisphosphate (PIP~2~), the precursor of PIP~3~, were not changed by the inhibitors ([Figure S3](#mmc1){ref-type="supplementary-material"}). We also investigated the IL-2 dependence of PIP~3~ production and noted that neither PIP~3~ levels nor AKT phosphorylation rapidly declined in IL-2-deprived CTLs ([Figures 7](#fig7){ref-type="fig"}K and 7L). Thus, IL-2R occupancy is not tightly coupled to PIP~3~ production, AKT activation, or FOXO1 phosphorylation and nuclear exclusion in CTLs. Rather, our data support a model where IL-2-JAK signaling integrates with IL-2-JAK-independent phosphorylation networks to program CTL fate ([Figure S3](#mmc1){ref-type="supplementary-material"}).

Discussion {#sec3}
==========

This study provides a systematic characterization and extensive documentation of the IL-2-regulated phosphoproteome and an SRC-family-kinase-controlled phosphorylation network in cytotoxic T cells. Our data afford new perspectives about the diverse Ser/Thr phosphorylations controlled by IL-2 to direct T cell biology and afford novel insights into critical signaling networks that can modify the outcome of IL-2 signaling and control CTL fate. We found that SRC family kinases regulated a substantial component of the CTL phosphoproteome and regulated phosphorylations that were distinct from those modulated by IL-2-JAK1/3. Links between SRC kinases and IL-2 signaling were first described 25 years ago ([@bib19], [@bib21], [@bib25], [@bib57]). We found no evidence that IL-2-JAK signaling stimulated LCK and/or FYN kinase activity; rather, a pool of active SRC family kinases was required to sustain the activity of critical Ser/Thr kinases, such as mTORC1 and AKT, in IL-2-stimulated CTLs.

One new insight from our data was that IL-2-JAK signaling had a complex impact on the nuclear environment of T cells beyond STAT5 nuclear translocation. The IL-2-JAK-regulated CTL phosphoproteome was dominated by proteins that regulate RNA, the protein translational machinery, vesicular trafficking, exocytosis, and the cytoskeleton. This diversity affords an explanation for the broad role of IL-2 as a regulator of the T cell biology. In particular, we noted that JAK activity linked the IL-2 receptor to regulatory phosphorylations on proteins that control mRNA stability and translation. This prompted the experiments that revealed that IL-2 sustained mRNA translation and protein synthesis in T cells. Thus, IL-2 can configure T cell proteomes independently of the transcriptional program. The ability of IL-2 to control rates of protein synthesis is a mechanism to explain the documented discordance between the transcriptome and proteome of IL-2-maintained CTLs ([@bib22]). Moreover, our results highlight that understanding how to manipulate IL-2 signaling for therapy needs to consider how IL-2 controls the biosynthetic capacity of the cell. The complexity of IL-2 signaling pathways in CTLs revealed by our data demonstrates the need for future studies that address the kinetics of phosphorylation events and determine if these pathways are always coordinately regulated or whether different thresholds of IL-2R occupancy activate different IL-2 signaling nodes.

Another important new perspective identified in this study was the relationship between IL-2R occupancy, JAK activity, and the control of PIP~3~-AKT signaling. Understanding how T cells regulate PIP~3~-AKT signaling is important, as the strength and coordination of AKT activity is pivotal for effector T cell differentiation ([@bib32]) and because immune function is impaired both by constitutive activation and by loss of PI3K-p110δ activity ([@bib1], [@bib30], [@bib42]). Current IL-2 signal transduction models place PIP~3~-AKT pathways downstream of JAKs. Our data force a revision of this model, as we found that, in CTL, the PIP~3~-AKT pathway was regulated by JAK-independent SRC-family-kinase-mediated signaling. The PP2 sensitivity of cellular PIP~3~-AKT signaling in CTLs suggests that IL-2-JAK signaling controls CTL function by integrating with pathways of lipid signaling and protein phosphorylation that are organized prior to IL-2R occupancy. The significance of "pre-organized" pathways of protein phosphorylation in T cells is increasingly recognized. For example, LCK activity is essential for antigen receptor signaling in T cells, yet LCK activity is constitutive and not controlled by antigen receptor occupancy ([@bib40]). Likewise, Myc expression in IL-2-maintained CTLs is defined by the constitutive activity of the Ser/Thr kinase GSK3 ([@bib47]), and the constitutive activity of HDAC7 Ser/Thr kinases ensures the nuclear exclusion of this key chromatin regulator in T cells ([@bib38]). The integration of IL-2-JAK signaling with pre-existing phosphorylation pathways may be a key determinant of the outcome of IL-2R occupancy and may explain how IL-2 can have pleotropic effects in different T cell populations. In particular, if the ability to activate AKT requires the activity of SRC family kinases, and not IL-2 regulated JAKs, our data offer an explanation for the failure of IL-2 to activate AKT in all T cells ([@bib5]).

In summary, our data uncovered amazing complexity of protein phosphorylation in CTLs. It revealed a dominance of Ser/Thr phosphorylations, but here, a proviso is that shotgun phosphoproteomics strategies can limit the detection of low-abundance Tyr phosphorylations. Indeed, our dataset did not detect Tyr phosphorylations of IL-2Rβ subunits or JAK1 and JAK3 previously mapped using phospho-Tyr enrichment protocols in the IL-2 dependent cell line, KIT225 ([@bib3], [@bib43], [@bib44]). It is also important to note that peptide identifications using SILAC require that proteolytic digests produce phosphopeptides of optimal size for mass spectrometry sequencing ([@bib18]). These must also contain an arginine or lysine, as these are the residues that allow phosphopeptide quantification in SILAC-based phosphoproteomics. The development of new mass spectrometry technologies and approaches may allow these limitations to be bypassed. Thus, future screens may produce further insights into signaling in CTL. Nevertheless, collectively, our study mapped over 18,000 phosphorylations in CTL, revealing new insights into the phosphorylation networks that direct the biology of these effector cells and providing a resource for further analyses and discovery.

Experimental Procedures {#sec4}
=======================

Mice {#sec4.1}
----

Mice were maintained in compliance with UK Home Office Animals (Scientific Procedures) Act 1986 in the University of Dundee. P14 T cell receptor transgenic mice ([@bib46]) and FOXO1-GFP mice, where GFP was fused to the C terminus of the endogenous FOXO1 gene ([@bib52]), have been described.

Cell Culture and SILAC Labeling {#sec4.2}
-------------------------------

Cytotoxic T Lymphocytes were generated as previously described ([@bib22], [@bib38], [@bib39]) and expanded in RPMI 1640 medium (Life Technologies) supplemented with 10% FBS (Life Technologies), 50 units/mL penicillin-G, 50 μg/mL streptomycin, and 50 μM β-mercaptoethanol and in the presence of 20 ng/mL IL-2 alone (Proleukin, Novartis). For SILAC labeling, CTLs were cultured for 5 days in SILAC RPMI 1640 medium (Life Technologies), supplemented with 200 mg/L L-proline, 84 mg/L L-arginine, 300 mg/L L-glutamate, 10% dialyzed FBS with a 10 kDa cutoff (Thermo Scientific), 50 units/mL penicillin-G, 50 μg/mL streptomycin, 50 μM β-mercaptoethanol, and 20 ng/mL IL-2. The "light" SILAC media contained L-\[12C6, 14N4\]arginine (R0) and L-\[12C6, 14N2\]lysine (K0). The "heavy" media contained L-\[13C6, 15N4\]arginine (R10) and L-\[13C6, 15N2\]lysine (K8).

For the IL-2 stimulation of CTLs, cells were "IL-2 quiesced" by the removal of IL-2 for 24 hr, but they were supplemented with 20 ng/ml IL-12 (R&D Systems) to sustain cell viability (at ∼90%) and the expression of the IL-2Rα chain (CD25). For the Tofacitinib and PP2 studies, CTLs were maintained only in the presence of IL-2, and no IL-12 was added to the culture.

Phosphoproteome Analysis {#sec4.3}
------------------------

Sample preparation was performed as described in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. Three independent biological replicate treatments were performed for each phosphoproteome analysis. The resulting mass spectrometry data were processed using MaxQuant version 1.5.0.0 ([@bib13]) and mapped to the reviewed UniProtKB-Swiss-Prot mouse protein database. The output from MaxQuant was filtered to remove known contaminants and reverse sequences before analysis. The distribution of SILAC ratios was normalized within MaxQuant at the peptide level so that the median of Log~2~ ratios was zero. Perseus software was used to annotate phosphosites, and the clustering tool in DAVID bioinformatics resources was used for functional annotation.

Flow Cytometry Analysis of Nuclear Extracts {#sec4.4}
-------------------------------------------

Cells (1×10^6^) were treated with 300 μL ice-cold nuclear extraction buffer (3.8 mM trisodium citrate, 9.6 mM NaCl, 0.05% NP-40), and the resulting nuclei were fixed immediately with ice-cold 300 μL IC fixation buffer (eBiosciences) for 15 min at 4°C. After washing, nuclei were stained with DAPI and analyzed using a fluorescence-activated cell sorting (FACS) LSRFortessa flow cytometer with DIVA software (BD Biosciences). Data analysis was performed with FlowJo software (Treestar).

Analysis of Protein Synthesis and Cellular Protein Mass {#sec4.5}
-------------------------------------------------------

Cells were treated with O-propargyl-puromycin (OPP, Jena Bioscience) for 10 min, and the incorporation of the aminoacyl-tRNA mimetic into newly synthesized polypeptides was measured by labeling the OPP was with Alexa 647-azide (Invitrogen) using a standard Click-IT chemistry reaction (Invitrogen). Cells were analyzed using a FACSVerse flow cytometer with FACSuite software (BD Biosciences) and analyzed with FlowJo software (Treestar). The protein mass of cells following different treatments was determined by BCA assay as per manufacturer's instructions (Pierce).

Mass Spectrometry Measurements of Inositol Lipids {#sec4.6}
-------------------------------------------------

Inositol lipid measurements were performed by mass spectrometry using 1 × 10^6^ cells per sample as described in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Author Contributions {#sec5}
====================

S.H.R. designed, performed, and analyzed most experiments; C.R. performed experiments and provided intellectual input; K.E.A. measured PIP~3~; P.T.H. and L.R.S. designed protocols for PIP~3~ measurements; D.A.C. and S.H.R. designed the project and wrote the manuscript.

Accession Numbers {#app1}
=================

The mass spectrometry phosphoproteomics data have been deposited to the ProteomeXchange Consortium (<http://proteomecentral.proteomexchange.org>) via the PRIDE repository with the dataset identifier identifiers [PXD004645](pride:PXD004645){#intref0015} and [PXD004644](pride:PXD004644){#intref0020}.

Supplemental Information {#app3}
========================

Document S1. Figures S1--S3 and Supplemental Experimental ProceduresTable S1. The Phosphoproteome of IL-2-Stimulated CTLs, Related to Figure 1All the phosphosites identified in three biological replicates of CTLs comparing the phosphoproteome of IL-2-quiesced CTLs (con) with IL-2-quiesced CTLs treated with 20 ng/mL IL-2 for 15 min (IL-2). Phosphosites ratios increased by 1.5-fold or greater are colored yellow, and those decreased by 1.5-fold or greater are highlighted in purple. The significance column shows the log-transformed p values (one sample t test). Values ≥ 1.3 are equivalent to p value ≤ 0.05.Table S2. The IL-2-Regulated CTL Phosphoproteome, Related to Figure 1 and Figure 2The phosphosites reproducibly regulated in two or three biological replicates of CTLs comparing the phosphoproteome of IL-2-quiesced CTLs (con) with quiesced CTLs treated with 20 ng/mL IL-2 for 15 min (IL-2) are shown. Phosphosites ratios increased by 1.5-fold or greater are colored yellow, and those decreased by 1.5-fold or greater are colored in purple. The significance column shows the log-transformed p values (one sample t test). Values ≥ 1.3 are equivalent to p value ≤ 0.05.Table S3. Functional Analysis of IL-2-Regulated Proteins, Related to Figure 1Groupings of proteins whose phosphorylation was reproducibly regulated by IL-2 in two or three biological replicates using DAVID cluster enrichment analysis.Table S4. The Phosphoproteome of IL-2-Maintained CTLs After 30 min of Tofacitinib Treatment, Related to Figure 3All the phosphosites identified in three biological replicates of CTLs comparing the phosphoproteome of IL-2-maintained CTLs (con) with IL-2-maintained CTLs treated with Tofacitinib (Tof) for 30 min. Phosphosites ratios increased by 1.5-fold or greater are colored yellow, and those decreased by 1.5-fold or greater are highlighted in purple. The significance column shows the log-transformed p values (one sample t test). Values ≥ 1.3 are equivalent to p value ≤ 0.05.Table S5. The Phosphoproteome of IL-2-Maintained CTLs After 4 hr of Tofacitinib Treatment, Related to Figure 3All the phosphosites identified in three biological replicates of CTLs comparing the phosphoproteome of IL-2-maintained CTLs (con) with IL-2-maintained CTLs treated with Tofacitinib (Tof) for 4 hr. Phosphosites ratios increased by 1.5-fold or greater are colored yellow, and those decreased by 1.5-fold or greater are highlighted in purple. The significance column shows the log-transformed p values (one sample t test). Values ≥ 1.3 are equivalent to p value ≤ 0.05.Table S6. Tofacitinib-Regulated Phosphosites in CTLs, Related to Figure 3Lists of phosphosites identified as being regulated by Tofacitinib treatment of IL-2-maintained CTLs. Phosphosites were included if they were regulated consistently in both datasets; consistently regulated in the 30-min dataset, but not detected in the 4-hr dataset; consistently regulated following the long-term Tofacitinib treatment but unchanged after 30 min of Tofacitinib treatment; or if they were consistently regulated after the 4-hr treatment, but not identified in the 30-min treatment. Phosphosites ratios increased by 1.5-fold or greater are colored yellow, and those decreased by 1.5-fold or greater are highlighted in purple. The significance columns show the log-transformed p values (one sample t test). Values ≥ 1.3 are equivalent to p value ≤ 0.05.Table S7. The IL-2-Independent Phosphoproteome, Related to Figures 1 and 3The phosphosites identified in the IL-2-stimulated dataset or Tofacitinib datasets but that were not found to be perturbed by the treatments are shown.Table S8. The CTL Tyrosine Phosphoproteome, Related to Figure 4All phosphotyrosine sites identified in the IL-2-stimulated dataset or Tofacitinib datasets are listed. Those with SRC family kinase motifs, or having been experimentally annotated as being SRC family substrates in the Phosphosite and ELM databases, are highlighted in yellow.Table S9. The Phosphoproteome of IL-2-Maintained CTLs After 4 hr of PP2 Treatment, Related to Figure 5All the phosphosites identified in three biological replicates of CTL comparing the phosphoproteome of IL-2-maintained CTL (con) with IL-2-maintained CTL treated with PP2 for 4 hr. Phosphosites ratios increased by 1.5-fold or greater are colored yellow, and those decreased by 1.5-fold or greater are highlighted in purple. The significance columns show the log-transformed p values (one sample t test). Values ≥ 1.3 are equivalent to p value ≤ 0.05.Table S10. The PP2-Regulated CTL Phosphoproteome, Related to Figure 5The phosphosites reproducibly regulated in two or three biological replicates of CTLs comparing the phosphoproteome of IL-2-maintained CTL (con) with IL-2-maintained CTL treated with PP2 for 4 hr are listed. Phosphosites ratios increased by 1.5-fold or greater are colored yellow, and those decreased by 1.5-fold or greater are colored in purple. The significance columns show the log-transformed p values (one sample t test). Values ≥ 1.3 are equivalent to p value ≤ 0.05.Table S11. The Integration of IL-2- and LCK/FYN-Mediated Signaling Pathways, Related to Figure 6The phosphosites reproducibly regulated by both 4 hr of Tofacitinib (Tof) and 4 hr of PP2 treatment. Phosphosites ratios increased by 1.5-fold or greater are colored yellow, and those decreased by 1.5-fold or greater are colored in purple.Document S2. Article plus Supplemental Information
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![Phosphoproteomic Analysis of IL-2 Maintained CTL\
(A) Experimental workflow for SILAC-based quantitative phosphoproteomic analysis of T cells.\
(B) CTLs differentiated as in (A) were starved of IL-2 for 24 hr in the presence of IL-12 to sustain expression of CD25 (IL-2 quiesced). The heavy-labeled CTLs were stimulated with 20 ng/mL IL-2 for 15 min mixed with the control (light) cells, and phosphopeptides were prepared. Phosphosites identified in three biological replicates are shown, with log-transformed SILAC ratios plotted against log-transformed p values (one sample t test); refer to [Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"} for identified phosphosites. Phosphosites with ratios reproducibly changed by 1.5-fold are shown in dark gray. The 50 phosphosites most reproducibly increased by IL-2 are shown in red and are displayed alongside. Phosphosites found to show a statistically significant regulation (p value ≤ 0.05) are marked with an asterisk (^∗^).\
(C) The overlap and correlation in the SILAC ratios of the phosphosites identified in the individual biological replicates is shown.\
(D) The numbers and percentages of phosphosites regulated in each replicate are shown.\
(E) CTL deprived of IL-2 and maintained in IL-12 were treated with or without IL-2 for 15 min and analyzed for STAT5 and ERK phosphorylation by immunoblot.\
(F) A schematic representation of the IL-2-regulated phospho-Tyr residues is shown.\
(G) The proteins regulated by phosphorylation in response to IL-2 were evaluated for function. The graph shows the cluster enrichment score as determined by DAVID analysis. See also [Table S3](#mmc4){ref-type="supplementary-material"}.\
(H) Overview of selected phosphosites regulated consistently by IL-2 in two or more experiments in proteins that regulate the cytoskeleton or vesicle transport.](gr1){#fig1}

![IL-2 Couples the Control of the Nuclear Environment with Translation\
(A) Schematic overview of selected phosphosites in nuclear proteins regulated consistently by IL-2 in quiesced CTLs in two or more experiments.\
(B) Immunoblot analysis of the phosphorylation of YBX1 in CTLs.\
(C) Schematic overview of mTORC1 signaling and translational machinery proteins identified in the IL-2 dataset. Phosphosites found to show a statistically significant regulation (p value ≤ 0.05, one sample t test) are marked with an asterisk (^∗^).\
See also [Table S2](#mmc3){ref-type="supplementary-material"}.](gr2){#fig2}

![Analysis of the Impact of the JAK1/JAK3 Inhibitor, Tofacitinib, on the IL-2-Maintained CTL Phosphoproteome\
(A) Immunoblot analysis of the STAT5 phosphorylation in CTLs maintained in IL-2 only over a time course of treatment with 100 nM Tofacitinib, a JAK1/3 inhibitor.\
(B and C) Heavy-labeled SILAC CTLs were treated with 100 nM Tofacitinib for 30 min (B) or 4 hr (C) before being mixed with control (light) CTLs for phosphoproteome analysis. Log-transformed SILAC ratios are plotted against log-transformed p values (one sample t test). See also [Figure S1](#mmc1){ref-type="supplementary-material"}, and refer to [Tables S4](#mmc5){ref-type="supplementary-material"} and [S5](#mmc6){ref-type="supplementary-material"} for lists of phosphopeptides. The graphs in (B) and (C) show the phosphosites identified in three biological replicates. Phosphosites with ratios reproducibly changed by 1.5-fold are shown in dark gray.\
(D) The impact of Tofacitinib on the IL-2-regulated Tyr phosphorylation sites is shown.\
(E) The heatmap shows phosphosites inversely regulated by IL-2 and Tofacitinib.\
(F) Tofacitinib-regulated phosphorylation sites identified in proteins involved in mRNA processing, transport, stability, and translation are shown. See also [Table S6](#mmc7){ref-type="supplementary-material"}.\
(D--F) Phosphosites found to show a statistically significant regulation (p value ≤ 0.05, one sample t test) are marked with an asterisk (^∗^).\
(G) Protein synthesis of CTLs maintained in IL-2 only, or IL-2 maintained CTL treated with 100 nM Tofacitinib (Tof) or deprived of any cytokines (WO) for different times was measured by puromycin incorporation using a flow-cytometry-based assay. Representative flow cytometry plots of the puromycin incorporation measurements are shown, with color-matched individual replicate data from three biological replicates shown alongside. The quantified protein content, as determined by BCA assay, of the same cells at each time point is shown in (H). Bars in (G) and (H) show the mean ± SD.](gr3){#fig3}

![The IL-2-Dependent and -Independent CTL Phosphoproteome\
(A--C) Average SILAC ratios for 4 hr Tofacitinib treated CTLs maintained in IL-2 only were plotted against average SILAC ratios for IL-2-stimulated quiescent (starved of IL-2 but maintained with IL-12) CTLs. All data are shown in light gray, with dark gray circles indicating the phosphorylation sites regulated by IL-2, but not by Tofacitinib; the black circles show the phosphorylation sites inversely regulated by IL-2 and Tofacitinib; and the red points showing the phosphosites on proteins grouped by their annotated GO functions in transcription (A), histone modification (B), or vesicle transport and the cytoskeleton (C). Selected phosphorylation sites regulated by IL-2, but not Tofacitinib, are shown below each graph.\
(D) Schematic representation of selected Tyr phosphorylated proteins identified in quiescent and IL-2 maintained CTL that are not regulated by IL-2 or JAK1/3 inhibition. Where identified phospho-Tyr residues fit a SRC family kinase motif, the protein is shown in red. See also [Table S8](#mmc9){ref-type="supplementary-material"}.\
(E) The location and function of certain identified Tyr phosphorylation sites is shown.](gr4){#fig4}

![Impact of the SRC Kinase Inhibitor, PP2, on the CTL Phosphoproteome\
(A) Immunoblot analysis of STAT5 pY phosphorylation in CTLs maintained in IL-2 only and treated with 10 μM PP2 or 100 nM Tofacitinib (Tof) for 1 hr.\
(B) Flow cytometry analysis of the expression of CD25 in IL-2-maintained CTLs treated without or with 10 μM PP2 for 24 hr. The histogram is representative of at least three experiments.\
(C and D) CTLs differentiated in IL-2 alone were treated with 10 μM PP2 or deprived of IL-2 (WO) for 24 hr, and the size of the cells was evaluated by flow cytometry and compared to IL-2-maintained controls. Representative FSC and SSC profiles are shown in (C), with mean FSC values of three color-matched biological replicates shown alongside. The protein content of the same cells was determined by BCA assay and is shown in (D). In (C) and (D), the bars show the mean ± SD.\
(E and G--J) Heavy-labeled SILAC CTLs differentiated and maintained in IL-2 alone were treated with 10 μM PP2 for 4 hr before being mixed with control (light) cells for phosphoproteome analysis. The regulated Tyr phosphorylation sites identified in the dataset were compared to those regulated by IL-2 and/or Tofacitinib (E). Protein names are shown in red when the identified phosphorylation site fits a SRC family kinase motif or is a known SRC family kinase substrate.\
(F) The immunoblot analysis shows the impact of a 30-min treatment of 100 nM Tofacitinib (Tof) or 10 μM PP2 on ERK phosphorylation in CTL maintained only in IL-2.\
(G) An overview of all the phosphosites identified in three biological replicates is displayed. Phosphosites with ratios reproducibly changed by 1.5-fold are shown in dark gray. See also [Figure S2](#mmc1){ref-type="supplementary-material"} and refer to [Tables S9](#mmc10){ref-type="supplementary-material"} and [S10](#mmc11){ref-type="supplementary-material"} for full lists.\
(H) Phosphosites regulated by 4 hr PP2 or 4 hr Tofacitinib treatment were evaluated for overlap.\
(I) The proteins with phosphorylation sites reproducibly regulated by 4 hr of PP2 treatment were evaluated for function. The cluster enrichment score as determined by DAVID analysis is shown.\
(J) Schematic representations of selected pS and pT signaling pathways perturbed by PP2 are shown in (J). In (E) and (J), phosphosites found to show a statistically significant regulation (p value ≤ 0.05, one sample t test) are marked with an asterisk (^∗^).](gr5){#fig5}

![Comparison of Tofacitinib- and PP2-Co-regulated Phosphosites in CTL\
(A) The heat map shows phosphosites residues reproducibly identified and co-regulated after 4 hr of Tofacitinib (Tof) or 4 hr of PP2 treatment in CTL maintained in IL-2 alone. Phosphosites found to show a statistically significant regulation in each condition (p value ≤ 0.05, one sample t test) are marked with an asterisk (^∗^). See also [Table S11](#mmc12){ref-type="supplementary-material"}.\
(B) Schematic representation of the mTORC1 pathway and the regulation of the phosphorylation of components by IL-2-JAK and LCK and/or FYN signaling, as determined by the phosphoproteomic analyses.\
(C) The phosphorylation status of S6, which is phosphorylated when mTORC1 is active, was quantified in CTLs maintained in IL-2 alone and treated with 100 nM Tofacitinib, 10 μM PP2, and 20 nM Rapamycin, the mTORC1 inhibitor, using a phospho-specific antibody and flow cytometry.\
(D) The phosphorylation status of the mTORC1 substrate, S6K (pT389) and its substrate S6 (pS235, pS236 and pS240, pS242) was determined in IL-2-maintained CTL by immunoblot. The data in (C) and (D) are representative of at least three experiments.](gr6){#fig6}

![Analysis of the PI 3-Kinase-AKT Signaling Pathway in CTL\
(A) The regulation of PRAS40/AKT1S1 in CTLs as determined by SILAC phosphoproteomics.\
(B and C) Immunoblot analysis of AKT phosphorylation in CTLs maintained in IL-2 alone and treated for 1 hr with 10 μM PP2, 100 nM Tofacitinib, 10 μM IC87114, a PI3K-p110δ inhibitor, or 1 μM AKTi, an AKT inhibitor (B) and in response to 1 hr IL-2 deprivation (C).\
(D--J) IL-2-maintained CTLs were generated from FOXO1-GFP mice. The localization of FOXO1-GFP (green) was visualized by microscopy (D), with the actin cytoskeleton detected using phalloidin (red). The scale bar is 5 μm. FOXO1-GFP levels in nuclear extracts of IL-2-maintained CTLs were quantified by flow cytometry under basal conditions (IL-2) and compared to a non-FOXO1-GFP-expressing CTL (WT) (E) or following 1 hr treatment with IC87114 (F), AKTi (G), PP2 (H), or Tofacitinib (Tof) (I). Representative flow cytometry profiles are shown in (F--I), with the level of FOXO1-GFP in each condition expressed as a ratio of the MFI of the IL-2 control of eight color-matched biological replicate treatments shown in (J), with bars showing the mean ± SD.\
(K and L) The levels of PIP~3~ in CTLs maintained in IL-2 only, shown as a ratio of the measured PIP~2~, were determined using mass spectrometry. In (K), IL-2-maintained CTLs were treated with 100 nM Tofacitinib (Tof), 10 μM PP2, 10 μM IC87114, or deprived of IL-2 (WO) for 30 min and compared to IL-2-maintained CTL control cells. In (L), PIP~3~ levels were measured in CTL maintained in medium alone (WO) and were compared to control (IL-2) and IL-2 + IC87114-treated cells for up to 2.5 hr. In (K) and (L), the left-hand panels show the data for a single experiment, with the immunoblot analysis of the phosphorylation of AKT on pT308 and pS473 shown in the middle panel. The right panel shows the results for color-matched biological replicates, 6 in (K) and 4 in (L). Bars show the mean ± SD.](gr7){#fig7}
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